Core Viewpoint - Morgan Stanley increased its stake in Innovent Biologics (01801) by purchasing 585,900 shares at a price of HKD 79.232 per share, totaling approximately HKD 46.422 million, raising its ownership to about 87.2176 million shares, which represents a 5.02% stake [1] Group 1 - Morgan Stanley's recent purchase of shares indicates a positive outlook on Innovent Biologics' future performance [1] - The total investment made by Morgan Stanley in this transaction is approximately HKD 46.422 million [1] - Following the acquisition, Morgan Stanley's total shareholding in Innovent Biologics is now approximately 87.2176 million shares [1]

鉴于通过医疗保健和生物制药生态系统中的集成价值链可能与中国基因集团产生的业务协同效应;收购 事项为一项策略投资机会，可令本集团扩大其在中国医疗保健及生物制药行业的市场参与度;及中国基 因集团因中国医疗保健及生物制药行业发展前景向好带来的绝佳机会录得的盈利纪录及其股息政策，预 计将在完成后为本集团的整体财务业绩及长期发展做出积极贡献，董事会(不包括独立非执行董事，彼 等将于考虑独立财务顾问的意见后发表意见)认为，协议及其项下拟进行交易的条款乃按正常商业条款 订立，属公平合理，且符合本公司及股东的整体利益。 于本公告日期，本集团暂无计划或意愿于可见将来进一步收购中国基因集团的股权。 中国基因集团的主要业务，与本集团现有的医疗保健产品贸易、医疗器械租赁及提供专业受托研究机构 (CRO)服务主营业务相辅相成。董事会认为，收购事项为一次绝佳机遇，令本集团参与中国基因集团的 业务营运(在中国医疗保健及生物制药行业前景向好的形势下，其业务不断发展、收益颇丰且具有强劲 的增长前景)，并进一步探讨本集团与中国基因集团之间可能的潜在业务合作。尤其是，本集团可透过 其医疗保健产品贸易业务下的广泛销售网路，以收费方式协助分销中国基因 ...

Group 1 - Company Changda Biological announced that its wholly-owned subsidiary, Changda Biological (Benxi) Co., Ltd., received approval from the National Medical Products Administration for clinical trials of a high-dose influenza virus split vaccine [1] - The approval highlights the long and uncertain development cycle of vaccine products, which may be influenced by various factors [1] Group 2 - Investors should exercise caution and consider investment risks associated with the vaccine development process [1] - Notable investments in the company include a joint investment of 1 billion yuan each from prominent investors Ge Weidong and Fang Wenyuan, leading to a significant increase in the company's stock price [1]

Core Viewpoint - Watson Bio has announced the establishment of the Yunnan Chuangwo Biological Industry Investment Fund, with a target size of 1 billion yuan, where the company will contribute 450 million yuan, accounting for 45% of the fund [1] Group 1: Investment Fund Details - The fund is initiated in collaboration with Guotou Chuangyi Industrial Fund Management Co., Ltd. and other parties [1] - The core investment focus of the fund is on synthetic biology, biomanufacturing, and biotechnology-related industries [1] Group 2: Strategic Implications - The establishment of the fund allows the company to closely engage with high-quality targets in the relevant fields [1] - This initiative is expected to provide rare opportunities for direct collaboration with target enterprises, laying the foundation for future industrial synergy and strategic mergers and acquisitions [1]

成大生物公告，全资子公司成大生物（本溪）有限公司收到国家药品监督管理局核准签发的《药物临床 试验批准通知书》（通知书编号：2026LP00405），批准流感病毒裂解疫苗（高剂量）开展临床试验。 本溪子公司申报的流感病毒裂解疫苗（高剂量），系用世界卫生组织（WHO）推荐的甲型和乙型流行 性感冒病毒株分别接种鸡胚，经培养、收获病毒液、纯化、病毒裂解、灭活后制成，有效成分是常规剂 量流感的四倍。 ...

Group 1 - The core point of the article is that Chengda Biologics (688739.SH) announced the approval of a clinical trial for a high-dose influenza virus split vaccine aimed at elderly individuals aged 60 and above, as well as high-risk groups with weakened immune systems [1] - The vaccine is expected to fill a gap in the domestic market for influenza prevention among vulnerable populations [1] - The company acknowledges that the development and commercialization process for the vaccine is lengthy, with uncertainties surrounding the clinical trial progress and product launch timeline [1]

证券日报网讯 2月12日，中牧股份在互动平台回答投资者提问时表示，公司第八届董事会审议通过了 《关于收购成都中牧生物药业有限公司65%股权的议案》，收购成都中牧65%股权，进一步丰富了公司 产品结构，布局新赛道，拓展新领域，具体内容详见公司公告。公司始终以开放的心态关注行业优质合 作机会，高度重视资源整合与优势互补机会，将持续关注国家及行业相关政策，力争实现新发展、新突 破。同时，公司始终注重价值创造和股东回报，向资本市场传递经营情况和投资价值，并将严格按照相 关规定及时履行信息披露义务。 （编辑 楚丽君） ...

Core Viewpoint - The company emphasizes the importance of cash management for idle funds and raised capital to maximize fund utilization efficiency [1] Group 1: Financial Strategy - The company has been increasing investments in channels, products, information technology, and supply chain since its listing, enhancing its one-stop service capability [1] - The company is focusing on self-product research and development, leading to rapid growth in its own brand and continuous optimization of its revenue structure [1] Group 2: Growth and Expansion - The company aims to integrate upstream and downstream resources through participation in industrial funds and investments, accelerating its expansion in the antibody and related fields [1] - The company is committed to strengthening its channel and product capabilities, striving for dual growth in profitability and sales performance [1]

Core Viewpoint - The recent developments of Sangfor Biopharma (688336.SH) focus on financial disclosures, product research progress, and partnership milestones [1] Financial Performance - The company announced a revenue forecast of approximately 4.2 billion yuan for 2025, representing a year-on-year growth of 251.76%, and a net profit of about 2.9 billion yuan, reflecting a year-on-year increase of 311.35%. This growth is primarily attributed to a licensing fee payment of approximately 2.89 billion yuan received from Pfizer for the SSGJ-707 project. However, these figures are preliminary estimates and subject to final audit [2] Product Development Progress - The company's core pipeline includes SSGJ-608 (for psoriasis) and SSGJ-613 (for acute gouty arthritis), both of which have submitted New Drug Applications (NDA) and are currently under review. Approval results are expected to be announced in 2026, and successful approvals could contribute to additional revenue [3] Business Development - The company is developing 22 projects in the autoimmune field, with 7 projects currently in Phase III clinical trials, such as SSGJ-611 for multiple indications. Clinical data announcements or application progress may occur in the future. The company plans to submit new drug applications annually from 2025 to 2028, indicating a promising long-term growth potential [4] Contract Developments - In May 2025, Sangfor Biopharma entered into a global licensing agreement with Pfizer for SSGJ-707 (a PD-1/VEGF dual antibody) with a total transaction value exceeding 6 billion USD. The upfront payment has been confirmed as revenue. The agreement includes development, regulatory, and sales milestone payments, which may trigger additional payments based on project progress, impacting the company's performance [5] Stock Performance - The company's stock has experienced volatility, with a cumulative decline of 6.83% over five consecutive days as of February 3, 2026. However, on February 6, the stock price rebounded to 60.00 yuan per share, with net inflows from major funds. Market reactions to the earnings forecast and research progress may continue [6]

经济观察网绿竹生物-B(02480.HK)是北京绿竹生物技术股份有限公司的上市主体，专注于疫苗及治疗性 生物制剂研发，核心产品为重组带状疱疹候选疫苗LZ901。该公司产品尚未商业化，收入主要依赖政府 补助，近期研发重心向后期临床及商业化转移。 近期事件 业绩经营情况 公司定期发布股份变动月报表(如最近一期截至2025年12月31日的报表于2026年1月7日披露)，未来新报 表的发布可能反映股东结构变化。2024年财务数据显示研发开支1.35亿元，税前亏损1.68亿元(同比收窄 32.5%)。投资者可关注2025年全年业绩公告，以评估经营改善情况。 公司状况 华证指数最新ESG评级(2025年10月31日)为BB，行业排名第25。未来若评级调整，可能影响机构投资者 关注度。 以上内容基于公开资料整理，不构成投资建议。 LZ901的生物制品许可申请(BLA)于2025年2月获国家药监局受理，目前处于正常审评阶段。作为核心管 线，其审评结果及后续商业化进程是市场关注焦点。 公司项目推进 公司临床前在研产品已增至六款，包括重组HSV-1疫苗(针对口腔疱疹)和重组HSV-2疫苗(针对生殖器疱 疹)。未来可能披露这些管线 ...